Loading...

APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  2. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  3. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  4. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  5. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  6. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  7. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  8. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  9. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  10. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  11. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  12. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  13. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  14. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  15. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  16. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  17. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  18. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  19. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  20. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  21. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  22. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  23. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  24. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  25. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  26. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  27. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  28. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  29. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  30. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  31. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  32. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  33. Diao L, et al. 2022. iScience. 25:105511. PubMed
  34. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  35. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  36. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  37. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  38. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  39. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  40. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  41. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  42. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  43. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  44. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  45. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  46. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  47. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  48. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  49. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  50. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  51. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  52. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  53. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  54. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  55. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  56. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  57. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  58. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  59. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  60. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  61. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  62. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  63. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  64. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  65. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  66. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  67. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  68. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  69. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  70. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  71. Mills C, et al. 2022. Cells. 11:. PubMed
  72. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  74. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  75. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  76. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  77. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  78. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  79. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  80. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  81. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  82. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  83. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  84. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  85. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  86. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  87. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  88. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  89. Harty J 2009. Infect Immun. 77:1894. PubMed
  90. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  91. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  92. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  93. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  94. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  95. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  96. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  97. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  98. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  99. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  100. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  101. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  102. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  103. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  104. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  105. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  106. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  107. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  108. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  109. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  110. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  111. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  112. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  113. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  114. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  115. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  116. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  117. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  118. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  119. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  120. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  121. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  122. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  123. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  124. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  125. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  126. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  127. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  128. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  129. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  130. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  131. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  132. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  133. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  134. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  135. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  136. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  137. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  138. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  139. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  140. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  141. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  142. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  143. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  144. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  145. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  146. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  147. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  148. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  149. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  150. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  151. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  152. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  153. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  154. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  155. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  156. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  157. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  158. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  159. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  160. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  161. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  162. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  163. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  164. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  165. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  166. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  167. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  168. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  169. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  170. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  171. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  172. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  173. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  174. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  175. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  176. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  177. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  178. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  179. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  180. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  181. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  182. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  183. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  184. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  185. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  186. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  187. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  188. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  189. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  190. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  191. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  192. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  193. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  194. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  195. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  196. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  197. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  198. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  199. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  200. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  201. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  202. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  203. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  204. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  205. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  206. Sheng J, et al. 2021. eLife. 10:00. PubMed
  207. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  208. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  209. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  210. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  211. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  212. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  213. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  214. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  215. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  216. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  217. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  218. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  219. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  220. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
  221. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  222. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  223. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  224. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  225. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  226. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account